Genmab — November 2017
-
The Dutch National Health Care Institute advising NOT to add daratumumab to the base Insurance package, unless price negotiations improve cost-effectiveness https://www.zorginstituutnederland.nl/publicaties/adviezen/2017/11/29/pakketadvies-daratumumab-darzalex-bij-multipel-myeloom
-
-
Are the Dutch the European mainland Scottish? Why not give it for free?

-
Det hele drejer sig vel bare om,at større investorer mener at de kan finde bedre afkastmuligheder på kort- eller mellemlang sigt end de kan i Genmab. Den slags er jo helt almindeligt forekommende i de fleste udviklingsselskabers historik.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind